Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2002-11-18
2010-06-08
Fay, Zohreh A (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S573000
Reexamination Certificate
active
07732487
ABSTRACT:
Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ to be transplanted can also be treated with the ClC-2 channel opener.
REFERENCES:
patent: 5096927 (1992-03-01), Ueno et al.
patent: 5100647 (1992-03-01), Agus et al.
patent: 5164415 (1992-11-01), Ueno
patent: 5166174 (1992-11-01), Ueno et al.
patent: 5225439 (1993-07-01), Ueno et al.
patent: 5254588 (1993-10-01), Ueno et al.
patent: 5256696 (1993-10-01), Ueno et al.
patent: 5284858 (1994-02-01), Ueno et al.
patent: 5317032 (1994-05-01), Ueno et al.
patent: 5380709 (1995-01-01), Ueno et al.
patent: 5428062 (1995-06-01), Ueno et al.
patent: 5739161 (1998-04-01), Ueno
patent: 5886034 (1999-03-01), Ueno et al.
patent: 6015828 (2000-01-01), Cuppoletti
patent: 6265440 (2001-07-01), Ueno et al.
patent: 6414016 (2002-07-01), Ueno
patent: 6469062 (2002-10-01), Ueno et al.
patent: 6566398 (2003-05-01), Ueno
patent: 2003/0130352 (2003-07-01), Ueno et al.
patent: 2027814 (1991-04-01), None
patent: 2030344 (1991-05-01), None
patent: 2030345 (1991-05-01), None
patent: 2030346 (1991-05-01), None
patent: 2041417 (1991-11-01), None
patent: 1312014 (1992-12-01), None
patent: 1323364 (1993-10-01), None
patent: 2150287 (1995-12-01), None
patent: 2279267 (1999-06-01), None
patent: 2377661 (2001-01-01), None
patent: 2404767 (2001-10-01), None
patent: 0 424 156 (1991-04-01), None
patent: 0435443 (1991-07-01), None
patent: 0978284 (2000-02-01), None
patent: 2-32055 (1990-02-01), None
patent: 01/76593 (2001-10-01), None
patent: 02/20007 (2002-03-01), None
patent: 02/089812 (2002-11-01), None
John Cuppoletti, Danuta H. Malinowska, Kirti P. Tewari. Qui-Ju Li, Ann M. Sherry, Myra L. Patchen, and Ryuji Ueno; SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2 chloride currents; Am. J. Cell Physiol. 287: C1173-C1183, 2004.
Lubiprostone; Drugs of the Future 2004, 29(4): 336-341.
Lubiprostone RU 0211, SPI 0211; Drugs in R & D, Adis International, Auckland, NZ, vol. 6, No. 4, 2005, pp. 245-248.
John Cuppoletti, et al. “C1C-2 C1 Channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole” American Journal of Physiol Cell Physiol 281: C46-C54, 2001.
Akira Ikari, et al. “Prostaglandin E2-Activated Housekeeping C1- Channels in the Basolateral Membrane of Rat Gastric Parietal Cells” Japanese Journal of Physiology, 49, 365-372, 1999.
Teodor G. Paunescu, et al. “PGE3Activation of Apical Membrane C1- Channels in A6 Epithelia: Impedance Analysis” Biophysical Journal vol. 81 Aug. 2001, 852-866.
Fay Zohreh A
Sucampo AG
Sughrue & Mion, PLLC
LandOfFree
Method for treating a disease or condition responsive to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a disease or condition responsive to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a disease or condition responsive to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175873